Innovent Biologics
About
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
- 5001 - 10000
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $2.42B
- Industries
- Biopharma,Biotechnology,Manufacturing
- Founded date
- Aug 1, 2011
- Number Of Employee
- 5001 - 10000
- Operating Status
- Active
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world.Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 4, 2022 | Post-IPO Equity | $2.42B | 1 |
Sanofi
|
— | Detail |
| Apr 27, 2018 | Series E | $150M | 1 | — | — | Detail |
| Nov 29, 2016 | Series D | $260M | 1 | — | — | Detail |
| Jan 22, 2015 | Series C | $115M | 1 | — | — | Detail |
| Nov 16, 2012 | Series B | $30M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Sanofi
|
Yes | Post-IPO Equity |
Lilly Asia Ventures
|
— | Series E |
|
|
— | Series D |
